SUNPHARMA1,850.00

Sun Pharmaceutical Industries Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersCIPLADRREDDYLUPINAPOLLOHOSPMAXHEALTHDIVISLABTORNTPHARMZYDUSLIFEMcap ₹4.44L Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations48,496.952,578.458,462.059,910.5
Other Income1,354.21,965.01,971.72,230.9
Total Income49,851.054,543.560,433.862,141.4
Expenses
+ Cost of Materials Consumed6,904.36,449.17,389.07,643.7
+ Purchases of Stock-in-Trade3,466.24,148.03,811.53,783.1
+ Changes in Inventories292.1150.3343.1265.3
+ Employee Benefit Expense9,429.19,973.111,418.911,844.4
+ Finance Costs238.5231.4338.9363.8
+ Depreciation & Amortisation2,556.62,575.42,937.92,976.0
+ Other Expenses15,382.116,586.317,768.118,526.6
Total Expenses38,268.840,113.544,007.445,402.9
EBITDA13,023.115,271.717,731.417,847.4
EBIT10,466.512,696.314,793.614,871.4
Profit
PBT before Exceptional Items11,582.214,430.016,426.416,738.5
+ Exceptional Items-494.3-677.9-1,307.5-693.6
Pretax Income11,087.913,752.115,118.916,044.9
+ Current Tax1,439.52,772.03,554.43,872.2
Tax Expense1,439.52,772.03,554.43,872.2
+ Share of Associates & JVs-38.4-15.4-55.9-55.7
Net Income9,610.010,964.811,508.712,117.0
+ Net Income — Continuing Ops9,648.410,980.111,564.512,172.7
+ Other Comprehensive Income1,142.1912.43,826.75,208.5
Total Comprehensive Income10,752.211,877.215,335.417,325.5
Net Income to Common9,576.410,929.011,479.412,095.6
Minority Interest33.735.729.221.4
Per Share
Basic EPS39.9045.6047.8050.40
Diluted EPS39.9045.6047.8050.40
Other Comprehensive Income — detail
+ Other Comprehensive Income912.43,826.75,208.5
+ Items NOT to be Reclassified to P&L734.7-45.1302.91,827.7
+ Tax on Items NOT to be Reclassified-11.6112.8275.6
+ Tax on Items NOT to be Reclassified — alt tag86.1
+ Items to be Reclassified to P&L502.7945.23,564.43,605.6
+ Tax on Items to be Reclassified-0.8-72.2-50.8
+ Tax on Items to be Reclassified — alt tag9.1
Comprehensive Income — Owners of Parent10,617.711,838.915,281.117,293.5
Comprehensive Income — Non-controlling Interests134.538.354.332.0
Per Share — as-filed variants
Basic EPS — Continuing Operations39.9045.6047.8050.40
Diluted EPS — Continuing Operations39.9045.6047.8050.40
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit37,834.241,831.146,918.448,218.4
Gross Margin %78.0179.5680.2580.48
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)11,582.214,430.016,426.416,738.5
− Exceptional Items (reconciliation)-494.3-677.9-1,307.5-693.6
Net Income Adj (tax-effected)10,040.211,506.012,508.712,643.2
EPS Adj41.6947.8551.9552.59
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value1.007,19,780.901.001.00
Paid Up Equity Capital239.9239.9239.9239.9
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 199%.